Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generex Biotechnology, a Canada-based provider of drug delivery system for metabolic diseases through the inner lining of the mouth firm, has received patents from Japan and Ukraine for its proprietary buccal drug delivery system.
Subscribe to our email newsletter
Generex has received the patent titled ‘Mixed Micellar Pharmaceutical Delivery System and Method of Preparation’ from The Commissioner of the Japan Patent Office. The patent number 449282 is registered in the Japan Patent Office.
The Ukrainian State Register of patents and inventions granted patent number 90346 entitled ‘Orally absorbed pharmaceutical formulation and method of administration.’
According to the Generex, the new patents increase the number of issued patents related to its buccal drug delivery platform technologies to 160. Moreover, a total of 103 patent applications are pending.
Rose Perri, chief operating officer of Generex, said: “Each new patent issuance establishes the inventiveness of the company’s buccal drug delivery platform technologies. We are pleased that we continue to receive patents from key markets within which our delivery system can be commercialized with a pipeline of viable applications that will open up other marketplaces for the company.”